July 2025 in “Frontiers in Pharmacology” This study highlights the potential of GPR30 and its selective agonists as promising therapeutic targets for treating hair loss disorders and conditions that respond to estrogen, emphasizing their role in modulating hair growth.
October 2024 in “Archives of Dermatological Research” The study found that patients with androgenetic alopecia had higher serum GPER-1 levels, which were associated with disease severity and duration, indicating a potential estrogen-independent role of GPER-1 in the condition's pathogenesis.
July 2025 in “The Egyptian Journal of Hospital Medicine” This study found that serum GPER-1 levels may serve as a biomarker for differentiating androgenetic alopecia from telogen effluvium and healthy controls, although its ability to distinguish between AGA and TE is limited.
July 2021 in “Archives of Dermatological Research” This study found that serum GPER-1 levels were significantly higher in patients with androgenetic alopecia compared to healthy controls, suggesting a potential role in the condition's pathogenesis, independent of gender.
1 citations
,
April 2006 in “International Journal of Oncology” In this study, lysocellin induced G1 phase arrest in human osteosarcoma cells, but diminished the cytotoxic efficacy of etoposide, while its derivative alopestatin may reduce etoposide-induced alopecia in a rat model.